Altimmune says ‘something raised attention of FDA’

At the Guggenheim Securities Healthcare Innovation Conference, Altimunne said “They mentioned in a recent publication that glucagon could have cardiotoxic effects So this is a reasonable study to do.” The company speculated that there might be something there that “raised the attention of the (FDA). We don’t know for certain.”